ASIO Past Events
ASIO Webinar-Science Communication for Scientists
Date: Monday, May 16, 2022
Time: 2:00 PM–3:00 PM EST
In this day and age of information overload, everyone seeks for bite-sized information, which is not only quick but also concise, and reproducible. In addition, it must be shareable and impactful. How does one communicate and be heard? It is increasingly important that as scientists we develop critical communication skills to talk not just with our peers but our future employers, colleagues and even our families. To this end, ASIO is bringing to you a webinar/workshop on science communication focused for Indian-Origin scientists. Manasi Apte, PhD, is a Scientist + Communicator, currently working at University of Tennessee, Knoxville. She has been involved in various public engagement and science communications initiatives in the United States and India for more than a decade. Through this webinar, she will be highlighting the importance of scientific communication skills in our careers and will incorporate critical elements such as “importance of an elevator pitch,” interview skills and how to improvise and deliver effective lectures and presentations.
Association of Scientists of Indian Origin (ASIO)-SOT Annual Meeting and Reception
Date: Monday, March 28, 2022 - Marriott Marquis San Diego Marina
Time: 5:00 to 9:00 PM PST
ASIO Webinar-Animal Models of COVID-19 Prevention and Treatment
Date: Friday, December 17, 2021
Time: 2:30 PM EST (GMT-05:00)
Description: Rapid development of vaccines that are protective against Covid-19 infection have been at the forefront of this war against the Sars CoV2 virus. Behind the scenes, there have been a several years of efforts in developing new modalities such as mRNA vaccines that can enable such scientific breakthroughs. In addition, advances and refinement in efficacy and safety testing animal models have been successful in building strong confidence in these vaccines technologies. Vaccine development for COVID-19 involves research work with multiple species to model the varied disease outcomes in humans. With each species reacting differently to the virus, we need to learn how best to exploit both differences and similarities to human responses in studies that reveal the nature of this disease and how best to control it.
The webinar on “Modeling SARS-CoV-2 infection in animals” This webinar will focus on highlighting animal models used to study SARS-CoV-2 infection and develop prevention/treatments against COVID-19
ASIO and CTPVSS Co-Sponsored Webinar: Health Effects of Tear Gas Agents
Thursday, February 25, 2021 at 12:00-1:00pm EST
Speaker: Satya Achanta, DVM, PhD, DABT, Assistant Professor in Anesthesiology, Duke University School of Medicine, NC, USA
Over the past several decades, CS (2‑chlorobenzalmalononitrile) tear gas has been used as a common riot-control agent (RCA) by law enforcement. The use of tear gas has dramatically increased in recent years, with very large amounts released in population centers in several countries. The conflicted use in Turkey, the United States, and Hong Kong drew widespread attention in recent times.
CS is a potent chemical irritant that activates transient receptor potential ankyrin repeat 1 (TRPA1) ion channels in sensory nerve endings in the cornea, skin, mucous membranes, and airways. TRPA1 activation elicits the sensation of pain and stimulates tear secretion, blepharospasm, sneezing, cough, vomiting, and profuse secretions in the respiratory tract. TRPA1 ion channels initially serve as warning sensors alerting to the presence of potentially injurious chemical exposures. However, extended activation during escalating tear gas use can lead to the activation of a downstream neurogenic inflammatory cascade. TRPA1 pathways also contribute to inflammation in dermatitis, conjunctivitis, asthma, and pulmonary edema, among many other diseases.
CS tear gas agent has been perceived to be a sublethal incapacitant and generally safe. However, more and more doubts have been raised about the safety of CS, especially due to additional corrosive chemical effects, secondary toxic products generated by heating, and observations of arrhythmogenic effects upon stimulation of the TRPA1 pathway. Reports from several countries describe widespread respiratory injuries in protesters. Therefore, the health effects and safety concerns need to be thoroughly studied.
The Visa Marathon: How to Navigate Your Way through the Changing Landscape of Visa Opportunities in the USA—September 24Webinar Recording
ASIO and ECDC Webinar: Staying Focused on Your Career: Challenges and Solutions for the Mid-Career Toxicologist
Date: Friday, March 6, 2020
Dr. S. Satheesh Anand, PhD, DABT
Association of Scientists of Indian Origin (ASIO) SOT Proudly Hosts the Webinar
Regulatory Network Models of Chemical-Induced Gene Perturbation
Date: December 15, 2017
“Interactive Meet for Insights in Toxicology” a ToxGurukul Initiative on Novembe, 25–26, 2017 at Bengaluru, India.
ASIO Annual Reception
Monday, March 13, 7:00 to 9:30 pm at the Hilton Baltimore, Peale Room
Career talk with Toxperts
Monday, March 13, 2017, 4:45 to 5:45 pm
Throughout the duration of the SOT Annual Meeting
ASIO is proud to announce Tox-Webinar on the latest developments of Immunology. The speaker is Dr. Prakash Nagarkatti, Distinguished Professor and Vice President for Research at University of South Carolina, Columbia. Dr. Nagarkatti is an expert immunologist and his recent research focus on cannabinoids and other AhR ligands as potential anti-inflammatory agents.
Topic: Inflammation—Can we silence the secret killer?
This webinar will introduce the basic mechanisms of inflammation triggered by innate and adaptive immune system. The key role of AhR ligands in suppressing inflammation and dietary compounds that act as AhR ligands will be highlighted in light to the recent developments in immunological research.
Topic: ASIO—Inflammation: Can we silence the secret killer?
ASIO initiated Tox-Webinar series last year with the goal to educate students and fellow scientists on the latest developments of toxicological sciences. Based on the valuable inputs from the members of Society of Toxicology, ASIO is planning to host a topic on chemical carcinogenesis. The speaker is Dr. Udayan Apte from University of Kansas Medical Center, who is an expert in hepatotoxicology and has extensive experience working on mechanisms of liver regeneration, hepatic stem cells and mechanisms of chemical carcinogenesis.
Webinar Topic: New Frontiers in Chemical Carcinogenesis
Date: Friday, Sep 26, 2014
This webinar will introduce the basic mechanisms of chemical carcinogenesis and will highlight recent new developments in carcinogenesis field. Apart from discussing the current trends, it will also provide perspectives how the new information can be applied to ongoing research efforts.
“Omics” Applications in Drug Discovery and Development
Date: Friday, Dec 13
Time: 12:00 noon–1:00 pm Eastern Standard Time, USA (EST)
The webinar will address the application of “omics” approaches as biomarker tools in drug discovery and development. Understanding transcription (mRNA, miRNA), translation (and its modifications) and the metabolites are fundamental to interrogate the mechanistic toxicity of complex human disease. The insights lend itself to develop biomarker signature for understanding mechanism of action of drug and its efficacy, patient enrichment and stratification in clinical trials. Thereupon, the biomarker platforms and technologies have evolved to provide practical applications as well as less resource-intensive approaches. The presentation will provide broad perspectives and examples on the “omics” approaches and their utilization in drug discovery and development as biomarkers.
Dr. Shashi Ramaiah is pioneer in the field of biomarker “Omics” technology and currently serving as the head of Translational Biomarkers at Pfizer Biotherapeutics in Cambridge, MA. He received his doctoral degree in veterinary medicine in 1992 from University of Agricultural sciences, Bangalore, India and received PhD in Toxicology from University of Lousiana at Monroe in 1999. He completed his clinical pathology residency at University of Florida, Gainesville in 2002 and became faculty of Texas and A & M College of Veterinary Medicine. He obtained an independent NIH funded research program on alcoholic liver disease and trained several graduate students, residents and post-doctoral fellows. He is board certified in clinical Pathologist (DACVP) and toxicologist (DABT). He has published more than 50 peer-reviewed journal articles, manuscripts and book chapters. Dr. Ramaiah transitioned from academia to Pfizer.Inc in 2008 as Translational biomarker head and is currently responsible for scientific leadership, supervision of laboratory operations and development of translational pharmacology and safety biomarker strategies to support projects across different therapeutic areas and modalities in Pfizer-Biotherapeutics portfolio.
Preclinical GLP Study Director Workshop
ASIO Annual Reception
ASIO Student/Post-Doc Mentoring Program
2011 Annual Meeting—Washington, DC
2010 Annual Meeting